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A
 
BSTRACT
Background:
 
The relationship between the severity of
atopic dermatitis (AD) and involvements of T helper
(Th) 1 and Th2 cytokines has not yet been clarified
yet. The aim of the present study was to understand
the relationship between the severity of AD and the
involvement of Th1 and Th2 cytokines. Thus, we deter-
mined cytokine production 
 
in vitro
 
 by peripheral blood
mononuclear cells (PBMC) obtained from patients with
AD before and after treatment.
 
Methods:
 
Cytokine production by PBMC obtained
from patients with AD following antigen stimulation
 
in vitro
 
 were compared before and after treatment.
Enzyme-linked immunosorbent assays were used to
measure cytokines. Treatment was undertaken with
topical steroids and oral antihistamines.
 
Results:
 
Interferon-
 
γ
 
 and interleukin (IL)-12 pro-
duction increased significantly after 2 weeks treatment
(
 
P
 
 < 0.005 and 
 
P
 
 < 0.05, respectively), while IL-10
production decreased significantly after 2 and 4 weeks
treatment (
 
P
 
 < 0.01). Granulocyte–macrophage colony
stimulating factor and tumor necrosis factor-
 
α
 
 pro-
duction increased significantly after treatment (
 
P
 
 < 0.05
and 
 
P
 
 < 0.05, respectively). The production of IL-1
 
β
 
,
IL-4 and IL-13 was not changed significantly.
 
Conclusions:
 
The T cells obtained from patients that
were involved in the active inflammation of atopic
dermatitis were predominately of the Th2 type and, in
addition, the function of these T cells was likely to be
affected by the intensity of the skin inflammation.
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I
 
NTRODUCTION
 
Atopic dermatitis (AD) is a chronic pruritic disease with
multifactorial causes, including both hereditary and
immunologic factors. IgE synthesis is increased in most
patients with AD. Previous studies have demonstrated
important roles for interleukin (IL)-4 and interferon
(IFN)-
 
γ
 
 in the regulation of IgE synthesis.
 
1–4
 
 In addition,
it has been reported recently that IL-13 is capable of
inducing IgE synthesis.
 
5
 
 The activating effect of IL-4 is
promoted by IL-5 and IL-6, but is inhibited by IFN-
 
α
 
 and
-
 
γ
 
 and transforming growth factor-
 
β
 
.
 
6,7
 
Based on the cytokine production profile, CD4
 
+
 
T helper (Th) cells can be divided into at least two cate-
gories, namely Th1 and Th2. The Th1 cells produce IL-2
and IFN-
 
γ
 
 and the Th2 cells produce IL-4, IL-5 and
IL-10.
 
8,9
 
 Interferon-
 
γ
 
 and IL-12 strongly promote genera-
tion of Th1 cells, whereas IL-4, and IL-10 promote Th2
cells.
 
10–12
 
 These cytokines are thought to have a key role
in the pathogenesis of AD.
Freshly isolated T cells and T cell clones from patients
with AD who are allergic to house dust mite (HDM) rec-
ognize several peptides derived from 
 
Dermatophagoides
pteronyssinus
 
 (Dp) and 
 
Dermatophagoides farinae
 
 (Df) and
they proliferate to produce Th2-type cytokines.
 
13–15
 
Preferential accumulation of allergen-specific Th2 cells
strongly implicates these cells in the establishment of the
skin lesion.
 
16,17
 
 However, little is known about how this
skin condition affects cytokine production 
 
in vitro
 
 by
peripheral blood mononuclear cells (PBMC) from
patients with AD.
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We investigated the relationship between the severity
of dermatitis, therapeutic effects and the production of
IFN-
 
γ
 
, IL-1
 
β
 
, IL-4, IL-10, IL-12, IL-13, TNF
 
α
 
 and
granulocyte–macrophage colony-stimulated factor (GM-
CSF) by PBMC from patients with AD following stimula-
tion 
 
in vitro
 
 induced by a specific antigen.
 
M
 
ETHODS
 
Patients and controls
 
The AD group consisted of 30 patients (15 male and
15 female; age range 9–36 years; mean (
 
±
 
SEM) age
21.6 
 
±
 
 5.5 years). All patients were classified as severe
cases of AD according to the SCORAD index (advocated
in the Consensus Report of the European Task Force on
Atopic Dermatitis).
 
18
 
 Certain modifications in grading
were made to monitor clinical changes in more detail.
 
18–20
 
To determine a score, the intensity of erythema, edema,
vesicles, papules, crusts, excoriations, lichenification and
itching was calculated by multiplying intensity times
distribution ratings to produce a score between 0 and
156. Clinical status and laboratory results (total IgE,
cortisol and RAST) were assessed at the same time points
when heparinized venous blood samples were obtained.
Patients were confirmed to be sensitized by the mite
antigen (Df) using the methods of skin tests and RAST
score. The mean (
 
±
 
SEM) serum IgE concentration before
treatment was 6662 
 
±
 
 1336 IU/mL and the mean (
 
±
 
SEM)
serum cortisol concentration was 9.99 
 
±
 
 0.66 
 
µ
 
g/dL
(Table 1). No patient had been treated by any means for
more than 2 weeks before the study. After initial blood
sampling, patients were treated with topical cortico-
steroids in combination with antihistamines, including
ketotifen, terfenadine, oxatomide and azelastine. Patients
with systemic steroid therapy were excluded from study.
When patients entered remission after 2–8 weeks treat-
ment, a second heparinized blood sample was obtained.
Peripheral venous blood was also obtained from
11 healthy, non-atopic controls (seven male and four
female; age range 25–38 years; mean (
 
±
 
SEM) age
29.1 
 
±
 
 10.7 years). Five of these control subjects had
blood sampling both before and after topical applica-
tion of corticosteroid (0.05% clobetasol propionate;
5 g/day) for 5 days.
 
Reagents
 
The Df extract was kindly provided by Torii Pharma-
ceutical (Tokyo, Japan). Purified mycobacterial protein
derivative (PPD) was purchased from Japan BCG (Tokyo,
Japan). In preliminary experiments, we determined the
optimal concentrations of Df extract (10 
 
µ
 
g/mL) and
PPD (1 
 
µ
 
g/mL) for use in the proliferation assays (data
not shown).
 
21
 
Cell preparation and culture
 
Experimental protocols were explained to all patients by
documents. Informed consent was obtained from each
patient.
Heparinized venous blood was obtained from 30
patients with severe or moderate AD that had been
untreated for at least 2 weeks. Blood also was obtained
later at the time of clinical remission upon treatment. The
PBMC were isolated by Lymphoprep centrifugation
(Nacalai, Kyoto, Japan) and then incubated with Df
antigen or phytohemagglutinin (PHA) for 72 h. As
another functional indicator in PBMC, incorporation of
thiamine deoxyribose ([
 
3
 
H]-TdR) into PBMC was deter-
mined after stimulation with Df antigen.
 
22
 
The PBMC were washed in phosphate-buffered saline
(PBS) and resuspended in RPMI 1640 (Life Technologies,
Gaithersburg, MD, USA) with 10% heat-inactivated fetal
calf serum at a cell density of 1 
 
×
 
 10
 
6
 
 /mL. The PBMC
(10
 
6
 
 /well) were cultured in a multiwell culture plate for
72 h with 10 
 
µ
 
g/mL Df antigen. As positive and negative
controls, other cells were cultured with PHA or with
medium alone, respectively. Supernatants from wells
were pooled for the measurement of cytokines after
storage at –70
 
°
 
C.
 
Table 1
 
Severity of atopic dermatitis and serum IgE and cortisol before and after treatment
Pretreatment Treatment
 
P
 
2 weeks 4 weeks
Severity score 82.6 
 
± 
 
7.4 24.2 
 
± 
 
3.1 15.7 
 
± 
 
2.5 0.0001
IgE (IU/mL) 6662 
 
± 
 
1336 8167 
 
± 
 
1666 8286 
 
± 
 
1503 NS
Cortisol (
 
µ
 
g/mL) 9.99 
 
± 
 
0.66 8.55 
 
± 
 
0.67 8.77 
 
± 
 
0.54 NS
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Cytokine measurement
 
Interleukin-4, IL-10, and IL-12 levels in supernatants
were measured by an ultrasensitive enzyme-linked
immunosorbent assay (ELISA; BioSource, Camarillo, CA,
USA). Interleukin-13 and IFN-
 
γ
 
 were also measured by
ELISA (BioSource), as were IL-1
 
β
 
, GM-CSF and TNF-
 
α
 
(Amersham, Buckinghamshire, UK).
 
Statistical analysis
 
For statistical analysis, data were compared by using the
Mann–Whitney 
 
U
 
-test, the Wilcoxon signed-rank test
and Pearson’s correlation coefficient. 
 
P
 
 < 0.05 was
considered statistically significant.
Unless stated otherwise, data are given as the
mean 
 
±
 
 SEM.
 
R
 
ESULTS
 
Production of Th1 cyokines (IFN-
 
γ
 
 and IL-12) 
by PBMC stimulated by Df antigen in patients 
with AD and normal subjects
 
Interferon-
 
γ
 
 and IL-12 production was detected in all
samples. Interferon-
 
γ
 
 production by PBMC induced by
10 
 
µ
 
g/mL Df antigen before treatment in atopic patients
was lower than in normal subjects (1.56 
 
±
 
 0.22 
 
vs
 
4.32 
 
±
 
 0.42 pg/mL, respectively; 
 
P
 
 < 0.001, Wilcoxon
signed-rank test). Similarly, IFN-
 
γ
 
 production before
treatment was lower than the normalized production that
followed treatment for either 2 or 4 weeks in the same
atopic patients (4.41 
 
±
 
 0.88 and 3.05 
 
±
 
 0.44 pg/mL,
respectively; 
 
P
 
 < 0.005 and 
 
P
 
 < 0.05, respectively,
Mann–Whitney 
 
U
 
-test; Fig. 1a). In contrast, the average
IL-12 production level before treatment was lower than
after 2 weeks treatment in the same atopic patients
(110 
 
±
 
 26.9 
 
vs
 
 180 
 
±
 
 32.9 pg/mL, respectively; P < 0.05,
Mann–Whitney U-test; Fig. 1b). No significant differ-
ences were noted for either cytokine between atopic
patients after treatment and normal subjects.
Production of Th2 cyokines (IL-10, IL-4, and 
IL-13) by PBMC
Interleukin-10, IL-4, and IL-13 production was also
detected in all samples. Interleukin-10 production
before treatment in atopic patients was higher than after
2 and 4 weeks treatment in the same atopic patients
(35.0 ± 7.30, 15.3 ± 3.27 and 13.5 ± 3.23 pg/mL,
respectively; P < 0.0005 and P < 0.005, respectively,
Mann–Whitney U-test; Fig. 1c).
Production of IL-4 in atopic patients before treatment
and after 2 and 4 weeks treatment was 0.77 ± 0.11,
0.94 ± 0.15 and 0.89 ± 0.13 pg/mL, respectively
(Fig. 1d). Production of IL-13 before treatment and after
2 and 4 weeks treatment was 9.99 ± 0.11, 13.4 ± 4.93
and 9.29 ± 2.04 pg/mL, respectively (Fig. 1e). No signif-
icant difference was noted in the production of IL-4 and
IL-13 between atopic patients before treatment, atopic
patients with treatment and normal subjects.
Production of pro-inflammatory cytokines 
(IL-1β, GM-CSF and TNFα) by PBMC
Concentrations of IL-1β produced by PBMC in response
to Df antigen before treatment and after 2 weeks
treatment were 99.7 ± 24.0 and 127.3 ± 27.8 pg/mL,
respectively (NS).
The production of GM-CSF by PBMC induced by Df
antigen before treatment and after 2 weeks treatment
was 26.1 ± 7.7 and 89.3 ± 33.4 pg/mL, respectively
(Fig. 2a; P < 0.05, Wilcoxon test).
To examine differences in cytokine production
between patients and healthy controls, the production of
GM-CSF by PBMC from healthy controls was determined
before and after topical corticosteroid application for
5 days; no significant difference was noted for pro-
duction in response to Df antigen between pre- and
post-treatment states. However, GM-CSF production
differed significantly between patients and controls before
treatment.
The production of TNF-α in response to Df antigen
by PBMC from AD patients before and after treatment
was 171.9 ± 59.1 and 357.7 ± 95.1 pg/mL, respec-
tively (Fig. 2b; P < 0.05). Tumor necrosis factor-α
production by PBMC from healthy controls was also
determined before and after topical corticosteroid appli-
cation, showing a significant difference in TNF-α pro-
duction between patients and control PBMC before
treatment.
Correlation between disease severity, IgE and 
T cell cytokine production in patients with AD
Symptom scores were estimated according to the
SCORAD index as described in the Methods section.
Changes in symptom scores and cytokine concentrations
were evaluated in 30 patients. According to Pearson’s
24 S KANEKO ET AL.
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correlation coefficient, serum IgE concentrations corre-
lated well with the clinical severity of AD (r = 0.541;
P < 0.002). However, no correlation was established
between IgE and the in vitro production of IFN-γ, IL-10,
IL-12, IL-4, or IL-13. Furthermore, no correlation was
found between symptom scores and cytokine concentra-
tions. Therefore, we performed a follow-up study to
investigate whether changes in the production of each
cytokine with treatment paralleled changes in symptom
severity. A significant correlation was observed between
changes in disease severity and changes in IFN-γ, IL-10
and IL-12, but not IL-4 or IL-13 (Fig. 3; Pearson’s
correlation coefficient).
DISCUSSION
Recent studies have demonstrated the involvement of
cytokines in the pathogenesis of allergic diseases.23,24 In
the present study, we investigated whether the severity of
AD reflected cytokine production by patients’ PBMC
Fig. 1 Cytokine production by peripheral blood mononuclear cells (PBMC) induced by 10 µg/mL Dermatophagoides farinae (Df)
antigen in patients with atopic dermatitis (AD). Thirty patients with moderate to severe AD were studied, as were 11 normal controls.
All AD patients had positive RAST scores for Df antigen. Patients had not received any systemic or topical therapy for at least 2 weeks
before this study. After initial blood cell sampling, patients were treated with topical steroids and oral antihistamines. The Df antigen-
induced production of cytokines by PBMC (106 cells/mL) from patients with AD over 72 h was determined before treatment and after
2 and 4 weeks treatment. (a) The production of interferon (IFN)-γ induced by Df antigen increased after 2 weeks treatment in patients
with AD compared with pretreatment production (4.41 ± 0.88 vs 1.56 ± 0.22 pg/mL, respectively; P < 0.05, Wilcoxon test). Less
IFN-γ production was noted in patients’ PBMC obtained before treatment than in cells from controls (4.32 ± 0.42 pg/mL;
P < 0.005, Mann–Whitney U-test). Production of IFN-γ at 4 weeks: 3.05 ± 0.44 pg/mL. (b) Production of interleukin (IL)-12
increased after 2 weeks treatment compared with pretreatment values (180 ± 33 vs 110 ± 27 pg/mL, respectively). Production of
IL-12 in controls and in AD patients after 4 weeks treatment was 88.2 ± 11.3 and 116 ± 26 pg/mL, respectively. (c) Production
of IL-10 decreased after 2 and 4 weeks treatment compared with pretreatment values (15.3 ± 3.27, 13.5 ± 3.23 and
35.0 ± 7.30 pg/mL, respectively). Production in normal controls was 15.24 ± 2.51 pg/mL. There was no significant change
in the production of (d) IL-4 and (e) IL-13 after treatment (0.77 ± 0.11, 0.94 ± 0.15, 0.89 ± 0.13 and 0.70 ± 0.11 pg/mL
IL-4 for pretreatment, 2 and 4 weeks after treatment and in controls, respectively; 9,99 ± 3.06, 13.4 ± 4.9, 9.29 ± 2.04 and
7.29 ± 1.93 pg/mL IL-13 for pretreatment, 2 and 4 weeks after treatment and in controls, respectively).
Fig. 2 (a) Granulocyte–macrophage colony stimulating factor (GM-CSF) and (b) tumour necrosis factor (TNF)-α production by
peripheral blood mononuclear cells (PBMC) induced by 10 µg/mL Dermatophagoides farinae (Df) antigen in patients with
moderate to severe atopic dermatitis (AD; n = 11) and normal controls (n = 8). All patients had positive RAST scores for Df antigen.
Production of cytokines by PBMC (106 cells/mL) from patients with AD and normal controls induced by Df antigen over 72 h was
determined before treatment (Pre) and after 2 weeks treatment (Post).
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stimulated in vitro with specific antigen. We sought to
determine which cytokines were most closely linked
to AD by assaying cytokines (IFN-γ, IL-1β, IL-4, IL-10,
IL-12, IL-13, TNF-α and GM-CSF) produced by
patients’ PBMC in vitro following stimulation with specific
antigen. The above cytokines are well known to regulate
T cell proliferation and production of IgE. However,
which cytokines are related directly to the inflammatory
Fig. 3 Correlation between disease severity and T cell cytokine production in patients with atopic dermatitis (AD). A significant
relationship was seen between treatment-related changes in the production of (a) interferon (IFN)-γ, (b) interleukin (IL)-12 and
(c) IL-10 and changes in the disease severity score (linear regression analysis).
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reaction in allergic diseases remains unclear. We found
disease-related alterations in cytokine production by
stimulated PBMC using ELISA.
In the present study, AD patients’ PBMC stimulated
with Df showed deficient production of IFN-γ, IL-12,
GM-CSF and TNF-α, but displayed increased IL-10 pro-
duction compared with results in controls or the values
from the same patients after clinically successful treat-
ment. In contrast, IL-4 and IL-13 production in AD
patients’ PBMC did not differ significantly from pro-
duction in control subjects’ PBMC. Furthermore, the
clinical severity score of AD showed a distinct correlation
with serum IgE values, and a significant relationship was
noted between changes in clinical severity score and
changes in the production of IFN-γ, IL-10 and IL-12.
Changes in IFN-γ and/or IL-10 as seen in vitro may have
contributed to regulative in vivo synthesis of IgE in these
patients. In addition, rates of change of clinical scores
and cytokine levels were considerable in the period from
first treatment to 2 weeks, so that Fig. 3 indicates almost
the first treatment interval. The data also suggest that
T cells from patients with active AD predominately show
a Th2 cytokine profile. Furthermore, T cell function
shows a relationship with AD severity.
Increased production of IL-10 in PBMC and in skin
from AD patients has been reported previously.24 The
possible actions of IL-10 in the pathogenesis of AD are
intriguing. Interleukin-10 inhibits Th1 cytokine produc-
tion, which may account for decreased IFN-γ production
by cultured PBMC from atopic subjects.25,26 Interleukin-
10 also induces mast cell proliferation,27 which may be
important in the allergic response.28 Furthermore, IL-10 is
known to inhibit T cell-mediated reactions, which could
be related to reduced allergic contact reactivity observed
in subjects with AD.29 Indeed, the proliferative response
of patients’ PBMC to Df allergen was profoundly
decreased before treatment compared with the response
after treatment (pretreatment stimulation index (SI) 1.35;
post-treatment SI 2.26; n = 7; P < 0.05). Interleukin-10
is known to inhibit cell-mediated immunity to bacterial
pathogens30 and its production in AD lesions may con-
tribute to frequent bacterial superinfections, such as
impetigo. This property of IL-10 supports our present
findings. While IL-10 induces B cell proliferation and syn-
thesis of IgM, IgG and IgA, this cytokine has no direct
effect on IgE production.31 Overproduction of IL-10,
then, was not the cause of IgE elevation in our patients
with AD and no relationship was seen between clinical
severity score and IL-10. Furthermore, no significant
difference in IL-10 production was seen between AD
patients and normal subjects. Thus, multiple factors
appear to mediate abnormal cytokine production of AD,
with IL-10 being one factor among several.
Reduced production of IFN-γ in PBMC from AD
patients in vitro has been reported previously.33,34 This
abnormality was found in neonates with AD and is con-
sidered to be a primary component of the atopic state.35
Reduced IFN-γ production reflecting reduced IFN-γ
mRNA expression in PBMC has been liked to elevated
serum IgE concentrations in atopic patients.36 Our study
showed a similar reduction in IFN-γ production in
patients, which normalized with treatment. Because IFN-γ
can inhibit IgE synthesis and (Th2) allergic reactions, this
cytokine is considered important in atopic disease.
Recently, histamine has been reported to markedly
reduce the production of a Th1-inducing cytokine,
namely IL-12.37,38 The observation implies a positive
feedback mechanism that would favor development of
Th2 responses in AD. Histamine is released during aller-
gic reactions. We suspect that antihistamines reduce
histamine release, permitting an increase in IL-12 that, in
turn, enhances IFN-γ production by PBMC. It has also
been shown that NK cells and γδ T cells, the important
IFN-γ producers,39 are profoundly decreased in patients
with AD. However, we did not test changes in frequencies
of monocytes in PBMC before and after treatment.
Further analysis is needed.
In a previous study, GM-CSF was shown to be over-
produced by keratinocytes in AD.23 The production of
TNF-α by PBMC of patients with AD was significantly
lower that of non-AD controls,40 but TNF-α is over-
produced in the dermis as well as an increase in adhesion
molecule expression in the skin of patients with AD.41
In contrast, the production of GM-CSF and TNF-α
from PBMC was suppressed in patients with AD before
treatment. Our data suggest that lesional cytokine pro-
duction may affect the function of patients’ PBMC.
Granulocyte–macrophage colony stimulating factor and
TNF-α may be derived from epidermal keratinocytes,
dermal monocytes or dendritic cells and have been
thought to play important roles in the induction and
progression of AD.
The increased IL-4 has been demonstrated in serum
from AD patients.42 In addition, in vitro studies of PBMC
or T cells from AD patients show increased production of
IL-4 after either specific or non-specific stimuli.32–34 In
contrast, we observed no significant differences in IL-4
and IL-13 production before and after treatment.
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Changes in the clinical severity may not affect the pro-
duction of these cytokines in the peripheral blood.
In conclusion, we found that the production of IFN-γ,
IL-10, IL-12, TNF-α and GM-CSF by PBMC stimu-
lated by specific antigen reflected the clinical severity
of AD.
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